INTEGRIN MEDIATED DRUG TARGETING.

摘要

The present invention relates to cytostatics which have a tumour specific action as a result of linkage to agr;vbgr;3 integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and agr;vbgr;3 integrin antagonist and at the same time the desired intracellular action in tumour cells as a result of their enzymatic or hydrolytic cleavability with release of the cytostatic.